Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of “Buy” from Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS) has been given a consensus recommendation of “Buy” by the six research firms that are currently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $25.20.

Several equities research analysts have recently commented on ATXS shares. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Wedbush restated an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Oppenheimer lifted their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research report on Tuesday, August 13th. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Finally, TD Cowen began coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 price target on the stock.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS opened at $11.74 on Friday. The stock’s 50-day simple moving average is $10.32 and its two-hundred day simple moving average is $11.32. The stock has a market capitalization of $644.68 million, a price-to-earnings ratio of -5.09 and a beta of 0.73. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). As a group, equities analysts forecast that Astria Therapeutics will post -1.62 earnings per share for the current fiscal year.

Institutional Trading of Astria Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC lifted its position in shares of Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,112 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Astria Therapeutics by 135.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 2,861 shares in the last quarter. AJOVista LLC bought a new position in shares of Astria Therapeutics during the 4th quarter valued at approximately $51,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Astria Therapeutics in the first quarter valued at $200,000. Finally, Panagora Asset Management Inc. bought a new stake in Astria Therapeutics in the fourth quarter worth $119,000. 98.98% of the stock is currently owned by institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.